This policy brief provides a summary of a recent review of the definition of rare diseases, high cost and how HTA has been used in the case of rare diseases in seven countries. The countries were purposively selected based on them having established HTA policies and availability of resources in the

Because of their rarity, rare diseases are often treated with what the industry refers to as ‘orphan drugs’. These group of drugs are quite expensive because of the fewer number of people suffering from such sickness and usually provide low profit to manufacturer compared to other common drug for n

Open data is widely recognized as valuable, especially during the COVID-19 pandemic, highlighting the need for up-to-date information systems, leading all sectors to acknowledge its significance in enhancing efficiency, fairness, and societal development. These open data movements observed during

MEAs aim at early access to high-cost innovative medicines at pre-determined terms that can ensure the financial sustainability of healthcare systems. However, their successful adoption hinges on a consideration of various factors to address the unique challenges faced by different nations. The a

Familial Hypercholesterolemia (FH) is a genetic disorder characterized by elevated cholesterol levels, significantly increasing the risk of heart disease. Early detection through genetic screening can play a crucial role in preventing serious health outcomes. This study marks the first global eco

201-369-2555HITA,HITAP,HTA,method guidelines,การประเมินความคุ้มค่าด้านสุขภาพ

This study is a development oriented research. The data is collected by participant observation, brainstorming with experts, and a questionnaire asking opinions and the satisfaction from stakeholders attending the meeting of “the prioritization of research topics” on January 22nd, 2010. There was a total of 120 research topics proposed by 66 ag

Presently, Cost-Effectiveness Analysis has been increasingly adopted in health technology assessment. In addition, it is recognized as an important tool for policy makers in the health care resource allocation decision making process. However, the presentation of Cost-Effectiveness Analysis results in terms of cost per Quality-Adjusted Life Year (Q

Impact of obesity on economics and quality of life in Thailand  Obesity is regarded as a disease that requires appropriate treatment. At the global level, obesity is ranked the 6th among factors that cause diseases. The economic impact of obesity is substantial. The objective of this study was to estimate that healthcare cost and cost of productiv

There is an increasing impetus to use economic evaluation to allow more explicit and transparent healthcare priority setting. However, an important question for policy makers is whether it is appropriate and feasible to introduce economic evaluation data into healthcare priority setting or resource allocation decisions. This project systematically